Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Production of Recombinant Therapeutic Proteins in Human Cells: Current Achievements and Future Perspectives

Full text
Picanco-Castro, Virginia [1] ; Biaggio, Rafael Tage [2] ; Cova, Dimas Tadeu [3, 1] ; Swiech, Kamilla [1, 2]
Total Authors: 4
[1] Univ Sao Paulo, Fac Med Ribeirao Preto, Reg Blood Ctr, BR-14049 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, BR-14049 Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, BR-14049 Ribeirao Preto, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: PROTEIN AND PEPTIDE LETTERS; v. 20, n. 12, SI, p. 1373-1381, DEC 2013.
Web of Science Citations: 13

Over the past 20 years the demand for recombinant proteins has increased significantly. Mammalian cell lines have been extensively used to produce recombinant proteins. This expression system offers several advantages over microbial systems, mammalian cells have the cellular machinery to promote the secretion of the recombinant product and the posttranslational modifications, like glycosylation that is present in many of recombinant therapeutic proteins in the market. Human cell lines have emerged as a new and powerful alternative for production of such products. These cells are able to produce recombinant proteins with posttranslational modifications more similar to their natural counterparts, producing proteins with human-like glycosylation pattern avoiding immunogenic reactions against epitopes nonhumans. This review presents the available human cell lines that can be used in pharmaceutical industry, the advantages of this expression system and the main efforts made in this field. (AU)

FAPESP's process: 12/04629-8 - Establishment of a production platform for recombinant therapeutic proteins in human cells
Grantee:Kamilla Swiech Antonietto
Support type: Research Grants - Young Investigators Grants
FAPESP's process: 12/02109-7 - Serum-free suspension adaptation of human cell lines
Grantee:Rafael Tagé Biaggio
Support type: Scholarships in Brazil - Master